The group claims a seven-day vein-to-vein time is unique, and says why this matters.

AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.

After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.

Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.